Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16161240 | 0.92 | KDM4E (0.49) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2775446 | 0.87 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2771955 | 0.85 | KDM4E (0.49) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL16162158 | 0.85 | CNR2 (0.46) | CNR1CNR2TDP1 | |
| SCHEMBL2772897 | 0.85 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2774623 | 0.83 | MAPT (0.43) | KDM4EMEN1MAPTKMT2ACNR1 | |
| SCHEMBL2905618 | 0.82 | CNR2 (0.66) | CNR1CNR2TDP1 | |
| SCHEMBL2908165 | 0.82 | CNR2 (0.52) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL16168866 | 0.81 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL16253223 | 0.80 | CNR1 (0.56) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181196-B2 | Pharmaceutical compounds | KEMOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | CYP3A43, CYP2D6, CYP2C9 | KDM4E 2316/4885MEN1 3132/4885MAPT 2021/4885 |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | KDM4E 996/4885MEN1 4799/4885MAPT 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.